NCT03747419View on ClinicalTrials.gov

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Bladder CancerMuscle Invasive Bladder Cancer
Interventions
DRUG

Avelumab

Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.

RADIATION

Radiation

Cancer treatment that uses ionizing radiation to kill cancer cells.

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02215

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03747419 - Avelumab and Radiation in Muscle-Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter